- $877.15m
- $371.52m
- $67.48m
Brief: Kura Oncology Announces Senior Executive Promotions
U.S. STOCKS ON THE MOVE-Regions Financial, Red Cat, Summit Materials
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, SPAR, Alphabet
Kura slides as licensing deal seen as reducing chances of buyout
U.S. RESEARCH ROUNDUP-Microstrategy, Snowflake, Target
Kura to partner with Kyowa Kirin for blood cancer drug; shares fall
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy (updated)
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy
Brief: Kura Oncology And Kyowa Kirin Announce Strategic Collaboration To Develop And Commercialize Ziftomenib In Acute Leukemias
Kura Oncology Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Kura Oncology Q3 Operating Expenses USD 59.884 Million
Kura Oncology Inc expected to post a loss of 63 cents a share - Earnings Preview
Brief: Kura Oncology Q2 Net Income USD -50.837 Million
Kura Oncology Inc expected to post a loss of 63 cents a share - Earnings Preview
Kura Oncology Inc expected to post a loss of 63 cents a share - Earnings Preview
Brief: Kura Oncology Reports Preclinical Data
Brief: Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
Kura Oncology Inc reports results for the quarter ended in March - Earnings Summary
Brief: Kura Oncology Q1 Net Income USD -49.525 Million